Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Ramat Gan, Israel, filed Form 6-K on March 2, 2021. The filing reports on a definitive agreement entered into on March 1, 2021, regarding a private placement of securities.
Key Financial Metrics
The filing details a capital raise rather than operational financial results. Key metrics include:
- Total Proceeds: Approximately $8.15 million (as referenced in the attached press release title).
- Units Issued: Aggregate of 1,152,628 units.
- Unit Composition:
- 916,316 units at $7.07 per unit (consisting of one ADS and warrants).
- 236,312 pre-funded units at $7.069 per unit (consisting of a pre-funded warrant and warrants).
- Placement Agent: Aegis Capital Corp. acted as the exclusive placement agent in the United States.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the execution of a private placement agreement to raise capital. The filing does not provide comparative financial data against a prior period to assess changes in operational performance.
Guidance, Outlook, and Risks
Management Commentary: The Company has agreed to file a registration statement with the SEC to register the resale of the Securities. The filing is incorporated by reference into existing registration statements on Form F-3 and Form S-8.
Risks and Contingencies:
- The Securities have not been registered under the Securities Act of 1933 and may not be sold in the United States absent registration or an applicable exemption.
- Sales are restricted in any state or jurisdiction where such offer or sale would be unlawful prior to registration or qualification.
The filing text does not provide specific guidance, outlook, or details on unusual items beyond the capital raise.
Investor Verification Checklist
- Verify the final closing date and actual proceeds received from the private placement.
- Confirm the terms of the Series A and Series B Warrants and the Pre-Funded Warrants.
- Review the attached Press Release (Exhibit 99.1) for specific use of proceeds.
- Monitor the filing of the registration statement for the resale of the Securities.